TriSalus Life Sciences, Inc. Common Stock
TLSI
TLSI: TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
moreShow TLSI Financials
Recent trades of TLSI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TLSI's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: System and method for selective pressure-controlled therapeutic delivery Aug. 02, 2022
-
Patent Title: Implantable dual pathway therapeutic agent delivery port May. 24, 2022
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Apr. 26, 2022
Federal grants, loans, and purchases
Followers on TLSI's company Twitter account
Number of mentions of TLSI in WallStreetBets Daily Discussion
Recent insights relating to TLSI
Recent picks made for TLSI stock on CNBC
ETFs with the largest estimated holdings in TLSI
Flights by private jets registered to TLSI